Gilead Sciences Reports Long-Term FINCH Data for Jyseleca in Rheumatoid Arthritis

Gilead Sciences today presented long-term follow-up data from the Phase 3 FINCH trials evaluating Jyseleca (filgotinib) in patients with rheumatoid arthritis. The data showed that Jyseleca maintained significant improvements in disease activity, physical function, and quality of life over long-term treatment. The safety profile remained consistent with previous observations.